ArticleInternational ophthalmology2025
Effect of topical ramucirumab in experimental corneal neovascularization model.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThis study aimed to compare the efficacy of topical Bevacizumab and Ramucirumab in an experimental corneal neovascularization model and to find the most effective Ramucirumab dose. MATERIALS AND
methodsIn the experiments, 42 Sprague Dawley rats were randomly divided into six groups (n = 7). Corneal cauterization was applied to all groups except Group 1. Group 1 did not receive any treatment. The sham group (group 2) was applied topical dimethylsulfoxide twice daily. Group 3 was administered topical bevacizumab drops (5 mg/ml) twice daily. Groups 4, 5 and 6 received topical ramucirumab drops at a dose of 2.5, 5 and 10 mg/ml twice daily, respectively. On the 14th day, corneal photographs of all rats were taken under general anesthesia and the percentage of corneal neovascular area was calculated. VEGF, VEGFR-2 and TRPM2 immune reactivity in corneas taken after decapitation was evaluated by immunohistochemical scoring method. TAS and TOS levels were measured in blood taken from rats, and apoptosis was evaluated using the TUNEL staining method.
resultsThe percentage of corneal neovascularization areas to the entire cornea was lower in groups 3, 4, 5 and 6 compared to the sham group. VEGF, VEGFR-2 and TRPM2 immunoreactivity was observed to be statistically significantly increased in the sham group compared to the control group (p < 0.05), It was observed that there was a statistically significant decrease in groups 3, 4, 5 and 6 compared with the sham group (p < 0.05), no statistically significant difference was observed between groups 3, 4, 5 and 6 (p > 0.05).
conclusionRamucirumab can be used as a new agent in the treatment of CNV by reducing the levels of VEGF and VEGFR-2, which are CNV markers. In addition, since TRPM2 was affected statistically significantly, we think that it may be a new proangiogenic factor in CNV.
Indexed as
Identifiers
41014395What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.